Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 2Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 3Thyroid Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 70Nivolumab 47Ipilimumab 27Specimen Handling 15Magnetic Resonance Spectroscopy 15trametinib 14Biopsy 13dabrafenib 11cemiplimab 11avelumab 11Cyclophosphamide 11binimetinib 10Radiotherapy 9CTLA-4 Antigen 9fludarabine 8encorafenib 7atezolizumab 7Radiosurgery 7Immunoglobulin G 7Disulfides 7Cisplatin 7fludarabine phosphate 6durvalumab 6tislelizumab 5relatlimab 5lenvatinib 5dostarlimab 5Pemetrexed 5Paclitaxel 5Introns 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × naporafenib × Dermatologic × Clear all
NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Novartis

Phase 2 Active not recruiting
134 enrolled
Dermatologic

Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

Erasca, Inc.

Phase 1 Active not recruiting
86 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06346067 2026-02-27

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Erasca, Inc.

Phase 3 Active not recruiting
78 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡